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erasmusmAbstract Purpose: To critically evaluate and conﬁrm previous results regarding the diagnos-
tic accuracy of digital mammography screening (DM), compared to screen-ﬁlm mammogra-
phy (SFM) in the whole Dutch screening programme, in the period of 2004–2010, during
which a full transition from SFM to DM was made.
Materials and methods: 1.5 million DM and 4.6 million SFM were read in the Dutch national
breast cancer screening programme in the period of 2004–2010. We evaluated recall rate,
detection rate, positive predictive value and tumour-size distribution for younger and older
women, for ﬁrst time participants and women having a timely subsequent screen. We com-
pared DM screens read by radiologists reading DM and SFM (DM-group) to SFM screens
read by these radiologists (SFM-group) and to SFM screens read by radiologists reading only
SFM (SFMonly-group).
Results: Recall rate was 2.0% (95% conﬁdence interval (C.I.): 2.0; 2.1) in the DM-group,
compared to 1.6% (95% C.I.: 1.6; 1.6) in the SFM-group and 1.6% (95% C.I.: 1.5; 1.6) in
the SFM only-group. The overall detection rates were 5.9/1000 screens (95% C.I.: 5.7; 6.0)
in the DM-group, 5.1/1000 screens (95% C.I.: 5.0; 5.2) in the SFM-group and 5.0/1000 screens
(95% C.I.: 5.0; 5.1) in the SFM only-group. Detection rate rose most markedly in younger
women (age 49–54) from 4.0/1000 screens to 5.1/1000 screens (p-value < 0.001). Positive pre-
dictive value (PPV) in DM rose from 18.4% (95% C.I.: 14.6; 23.1) in 2004 to 32.5% (95% C.I.:
31.7; 33.2) in 2010. Detection rate rose in SFM-group from 5.0/1000 screens (95% C.I.: 4.7;
5.3) in 2004 to 5.5/1000 screens (95% C.I.: 5.2; 5.7) in 2010. Detection rate in DM-group rose
mostly due to ductal carcinoma in situ (DCIS) detection especially in younger women/ﬁrst
screens. The proportion of T1a tumours was signiﬁcantly higher in DM-group; otherwise sizelsevier Ltd. All rights reserved.
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3518 P.A. van Luijt et al. / European Journal of Cancer 49 (2013) 3517–3525distribution did not change signiﬁcantly for invasive carcinoma. Recall rates were variable
between different screening regions.
Conclusion: In accordance to previous, smaller, studies, we can conﬁrm that DM has a higher
detection rate compared to SFM, at the cost of a higher recall rate and lower PPV. More
DCIS and a higher fraction of very small tumours were detected with DM, which has positive
consequences for the stage shift as a result of mass screening.
 2013 Elsevier Ltd. All rights reserved.1. Introduction
The independent UK Panel on Breast Cancer Screen-
ing recently published their review.1 They state that in
light of the current debate on breast cancer screening
the beneﬁts outweigh the harms. This panel based their
decisions on data from screen-ﬁlm mammography
(SFM), some of which were from decades ago. The con-
sequences of a transition of the programme to digital
mammography (DM) were not yet fully elucidated.
The Dutch screening programme was implemented in
1990. All targeted women aged 50–75 receive an invita-
tion for screening mammography, free of charge, every
other year. The attendance rate is approximately 80%.
A feasibility study was carried out between 2003 and
2007 to ascertain whether it was feasible to convert to
digital mammography in the screening programme.2
Since June 2010 all mammography screening in the
Netherlands is performed digitally. In the recent past
ﬁve studies were performed in the Netherlands, based
on data of the feasibility study or from a single
region.2–5 These studies all found a higher recall rate,
higher detection rate and lower positive predictive value
(PPV). Decision making in service screening in Europe is
based mainly on population based data. Sometimes in
depth information can only be manually extracted
because it is not readily available in national data. The
disadvantage of this is a lack of power. Since we observe
considerable regional diﬀerences we wondered how a
very large, national data set would relate to national
and international communications on diﬀerences
between SFM and DM.
All over Europe and elsewhere studies were conducted
on the impact of a transition to digital mammography
screening.2–12 All studies found that the diagnostic preci-
sion of DM was at least similar to that of SFM, however
some found a higher recall rate and lower PPV,4–6 where
others found a similar or higher PPV.2,3,7–11 No clear cut
results on invasive stages/ductal carcinoma in situ
(DCIS) were published. The diﬀerences in published out-
comes may be explained by sample size and study design.
We retrospectively used the annual monitoring
parameters in more than 1.5 million DM and 4.6 million
SFM to assess performance during the transition from
SFM to DM. As our study covers all screening examin-
ations performed within the nation-wide breast cancer
screening programme and therefore has a larger externalvalidity, also it enables us to compare diﬀerences
between regions.2. Materials and methods
2.1. Case selection
All women aged 50–75 (corresponding with ages
49–74 at the beginning of a calendar year) receive a per-
sonal invitation biennially for mammography screening.
By participating in the programme, women automati-
cally consent to the use of their data to evaluate and
improve the programme. Information about the use of
data is provided in a ﬂyer accompanying the invitation
letter. If a woman does not want the screening organisa-
tion to use her data for this purpose, she can return the
signed corresponding form to the screening organisa-
tion. Only a minor fraction (0.01%) used this
possibility.13
We retrospectively evaluated the aggregated data
over the years 2004–2010 from the regional screening
organisations, which is delivered to us annually for
the purpose of monitoring the nation-wide pro-
gramme. We had information on age of the women
invited and attending, screening round and screening
results, whether the examinations were digital or
screen-ﬁlm and if radiologists were reading DM
(always in combination with SFM at some point in
time), SFM (in this case in combination with DM at
some point in time) or only SFM (a group that dimin-
ished to zero in 2010).
In 2007 the roll out of digital screening was initiated
nationwide, one screening unit at a time. Because several
screening units are attached to one radiologists’ group
(so-called reading unit), this gradual roll out resulted
in reading units reading both DM and SFM at a given
time.
This gave us the opportunity to analyse our data by
the type of reading unit that evaluated the screens:
1. DM read by a reading unit reading both SFM and
DM, we will refer to this group as DM-group.
2. SFM read by a reading unit reading both SFM and
DM, we will refer to this group as SFM-group.
3. SFM read by a reading unit reading only SFM, we
will refer to this group as SFM only-group.
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ing their ﬁrst screening examinations aged 49–51, on
women attending subsequent screens performed within
the appropriate screening interval of 2.5 years (we will
refer to these as timely subsequent screens) aged 50–
74, on younger women aged 49–54 and on older women
aged 55–74 for ﬁrst and subsequent screens together.
Our main outcome measures were recall rate (the
number of women recalled for clinical assessment,
based on suspicion of malignancy and inconclusive
results per 1000 women screened), detection rate (the
number of women diagnosed with breast cancer as a
result of screening per 1000 women screened), PPV
(the percentage of recalled women diagnosed with
breast cancer) and stage distribution of screen-detected
breast cancers (based on size and invasion). Because
detection rate overall increased, stage distribution was
expressed by the proportion of all detected tumours
to indicate diﬀerences in stage shift, rather than
increased detection.
The data contained information on the reading unit
(reading SFM, DM or both), on the number of women
initially or subsequently screened, on the interval period
between screens and on the number of recalls and
screen-detected breast cancers. From the 6,370,556
screens performed between 2004 and 2010, we excluded
women older than 74, because they represent very small
numbers (n = 7548), women who had their ﬁrst screen at
an age older than 51 years (n = 90,665), and women
with a subsequent screen after a screening interval of
more than 2.5 years (n = 264,761). The latter two groups
were expected to have a higher detection rate, dependent
on age-speciﬁc incidence and the average screening
interval.13 After exclusion 6,007,582 screens were left
for analysis.2.2. Screening radiologists
A Dutch screening radiologist has to be certiﬁed for
screening in the national service screening programme.
This can be achieved by participating in an eight days
training in the National Training and Reference Center
(NETC) in Nijmegen. The mean reading volume is
13,000 screens per year with a range from 3000 to
60,000. Increasing numbers of screening organisations
are now routinely performing two view mammogra-
phies. In 2010 93% of all screens were performed with
two view mammography.2.3. Data analysis
We retrospectively analysed the aggregated data for
the DM and SFM screens for the following outcome
measures: recall rate, detection rate, positive predictive
value and tumour size distribution of screen-detected
carcinomas. Each screening examination is one event,regardless of the number of mammography views,
lesions or malignancies.
During the study period 2004–2010, we compared
outcome measures and trends between the SFM-group,
DM-group and SFM only-group and between ﬁrst
screens, timely subsequent screens and ﬁrst screens and
timely subsequent screens together. Additionally we
stratiﬁed results by age-group, 49–54 and 55–74.
Because the detection of DCIS rose markedly we
decided to analyse the proportion of disease stages in
invasive breast cancer separately from the DCIS. The
proportion of DCIS is of the total number of screen-
detected breast cancer, the proportions of T1a, T1b,
T1c and T2+ are of the sum of all invasive cancers
(explicitly not including DCIS).2.4. Spread of outcomes by region
We also looked at the spread of outcomes between
diﬀerent regions. During the study period, the Nether-
lands had nine diﬀerent screening regions. They were
allocated letters A through I. Each screening region con-
tained a variable number of reading units. The results by
region were divided in the DM-group and the SFM-
group, for the SFM only-group we did not have data
per region, and by women aged 49–54 and women aged
55–74.2.5. Statistical analysis
All rates have been age-adjusted by direct standardi-
sation using the Dutch female population in 2000 as a
reference population. We used linear regression to test
for diﬀerences in proportions between DM and SFM
and we stratiﬁed by age. p-Values less than 0.05 were
considered signiﬁcant. All regression analyses were done
using R.3. Results
In total 6,007,582 screens were included for analysis.
Of these 1,452,508 (24%) were DM, 1,460,344 (24%)
SFM in the SFM-group and 3,094,730 (52%) SFM in
the SFM only group (Table 1). There was no diﬀerence
between the groups regarding age and the distribution of
the ﬁrst and subsequent screens. In 2010 there were no
more reading units reading only SFM.3.1. Overall
With regard to the overall results of the three
diﬀerent groups of reading units, across the years the
DM-group had a signiﬁcantly higher recall rate of
2.0% (95% conﬁdence interval (C.I.): 2.0; 2.1) than both
the SFM-group with 1.6% (95% C.I.: 1.6; 1.6) and the
SFM only-group with 1.6% (95% C.I.: 1.5; 1.6)
Table 1
Descriptive statistics. The percentage indicated in the screening round is the percentage of all screens in that group, the percentage indicated in the
number of screens is the percentage of a group of all screens in that year. Timely screen = a subsequent screen within 2.5 years since the previous
screen. DM = digital mammography, SFM = screen-ﬁlm mammography. DM-group = DM-screens read by radiologists reading both SFM and
DM, SFM-group = SFM-screens read by radiologists reading both SFM and DM, SFM only-group = SFM screens read by radiologists reading
only SFM.
DM SFM SFMonly
N = 1,452,508 N = 1,460,344 N = 3,094,730
l l l
Mean age 59.69 59.62 59.58
N % N % N %
Screening round
First screen 164,652 11 165,225 11 351,892 11
Timely subsequent screen 1,287,856 89 1,295,119 89 2,742,838 89
Number of screens
2004 9,342 1 177,180 21 643,998 78
2005 33,087 4 161,015 19 643,541 77
2006 39,494 5 153,337 18 640,800 77
2007 62,744 7 175,429 20 621,628 72
2008 87,055 10 364,710 42 419,069 48
2009 364,041 42 375,360 43 125,694 15
2010 856,745 94 53,313 6 n.a. n.a.
2004–2010 1,452,508 24 1,460,344 24 3,094,730 52
Table 2
Overall results and results by subgroup: women aged 49–54, women aged 55–74, ﬁrst screens and timely subsequent screens. p-Values less than 0.05
are considered signiﬁcant and indicated in bold. DM = digital mammography screen, SFM = screen-ﬁlm mammography screen,
DM-group = DM-screens read by radiologists reading both SFM and DM, SFM-group = SFM-screens read by radiologists reading both SFM
and DM, SFM only-group = SFM screens read by radiologists reading only SFM. PPV = positive predictive value.
Screens Recalls Recall
rate (%)
p-Value Cancers Detection
rate/1000 screens
p-Value PPV p-Value
Overall DM-group 1,452,508 29,363 2.0 8474 5.9 31.2%
SFM-group 1,460,344 22,799 1.6 <0.001 7382 5.1 <0.001 34.4% <0.001
SFMonly-group 3,094,730 47,683 1.6 <0.001 15,407 5.0 <0.001 34.2% <0.001
49–54 years (ﬁrst
screens 49–51 years,
timely subsequent
screens 50–74 years)
DM-group 429,692 11,973 2.7 2247 5.1 21.4%
SFM-group 434,064 8882 2.0 <0.001 1773 4.0 <0.001 22.1% 0.23
SFMonly-group 932,129 18,369 1.9 <0.001 3835 4.1 <0.001 23.0% <0.001
55–74 years (timely
subsequent screens)
DM-group 1,022,816 17,390 1.7 6227 6.2 35.7%
SFM-group 1,026,280 13,917 1.4 <0.001 5609 5.6 <0.001 40.1% <0.001
SFMonly-group 2,162,601 29,314 1.4 <0.001 11,572 5.5 <0.001 39.4% <0.001
First screen (49–
51 years)
DM-group 164,652 7422 4.6 1103 7.0 15.2%
SFM-group 165,225 5359 3.3 <0.001 880 5.5 <0.001 16.5% 0.05
SFMonly-group 351,892 10,773 3.2 <0.001 1862 5.6 <0.001 17.6% <0.001
Timely subsequent
screen (50–74 years)
DM-group 1,287,856 21,941 1.6 7371 5.3 30.6%
SFM-group 1,295,119 17,440 1.3 <0.001 6502 4.6 <0.001 33.5% <0.001
SFMonly-group 2,742,838 36,910 1.7 <0.001 13,545 4.6 <0.001 33.4% <0.001
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screens in DM-group (95% C.I.: 5.7; 6.0), versus 5.1
(95% C.I 5.0; 5.2) and 5.0 (95% C.I.: 4.9; 5.1) in
SFM-group and SFM only-group, respectively). PPV
was signiﬁcantly lower in DM-group at 31.2% (95%
C.I.: 30.6; 31.7) compared to 34.4% (95% C.I.: 33.8;
35.0) and 34.2% (95% C.I.: 33.7; 34.6) in SFM-group
and SFM only-group, respectively.3.2. Trends
In the DM-group the recall rate dropped rapidly
from 3.4/1000% (95% C.I.: 3.1; 3.8) in 2004 to 2.0/
1000% (95% C.I.: 2.0; 2.0) in 2010, and the detection
rate dropped from 6.5/1000 screens (95% C.I.: 5.1; 8.4)
in 2004 to 5.9/1000 screens (95% C.I.: 5.7; 6.1) in 2010
after an initial increase in the pilot, stabilizing at a lower
2007 2.242718 0.113373 0.119264 1.567533 0.057443 0.059592 1.753994 0.032478 0.03308
2008 1.997466 0.090828 0.095062 1.591928 0.040257 0.041285 1.876194 0.040697 0.041582
2009 2.019428 0.045289 0.046306 1.727759 0.041311 0.042305 1.826695 0.072979 0.075957
2010 1.985885 0.029356 0.029788 1.50368 0.099926 0.106923
DM-group ll ul SFM-groupll ul SFM-only-gll ul
2004 6.527978 1.456104 1.870613 4.98091 0.318262 0.33987 4.670696 0.164328 0.170292
2005 5.431491 0.748269 0.867069 4.456174 0.316238 0.340278 4.774352 0.166304 0.172276
2006 5.407286 0.681008 0.778525 4.473203 0.321881 0.346718 5.14947 0.173496 0.179513
2007 6.378352 0.595196 0.656019 5.049304 0.322796 0.344722 5.312182 0.178429 0.184596
2008 5.474116 0.469675 0.51349 5.416409 0.233674 0.24415 5.387368 0.217848 0.226976
2009 5.816423 0.241684 0.252097 5.539495 0.232579 0.242713 4.916183 0.373353 0.403873
2010 5.892904 0.160091 0.164534 3.669948 0.479877 0.551759
2008 0.292987 0.021362 0.022315 0.353798 0.01235 0.012548 0.31479 0.010468 0.010659
2009 0.305649 0.010611 0.010821 0.350539 0.011797 0.011983 0.294429 0.018876 0.019608
2010 0.324523 0.007177 0.00726 0.266105 0.030305 0.032677
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Fig. 1. Recall rate per 1000 screens (1a), detection rate per 1000 screens (1b) and positive predictive value at screening (PPV, %) (1c), development
over time. DM = digital mammography, SFM = screen-ﬁlm mammography. DM-group = DM-screens read by radiologists reading both SFM
and DM, SFM-group = SFM-screens read by radiologists reading both SFM and DM, SFMonly-group = SFM screens read by radiologists
reading only FSM.
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from 18.5% (95% C.I.: 14.6; 23.1) in 2004 to 32.5% (95%
C.I 31.7; 33.2) in 2010 and also stabilised, but at a higher
level (Fig. 1c). In the SFM-group recall rate and detec-
tion rate rose up to and including 2009 (recall rate went
from 1.5/1000 (95% C.I.: 1.4; 1.6) in 2004 to 1.7/1000
(95% C.I.: 1.7; 1.8), detection rate went from 5.0/1000
(95% C.I.: 4.7; 5.3) to 5.5 (95% C.I.: 5.3; 5.8)), resulting
in an overall unaltered PPV (35.1% (95% C.I.: 33.9;
36.3) in 2009). In 2010, all three parameters dropped,
probably as a result of smaller numbers of screening
examinations (see Table 1). Finally, in the SFM only-
group recall rate increased, from 1.3% (95% C.I.: 1.3;
1.3) in 2004 to 1.8% (95% C.I.: 1.8; 1.9) in 2009, butdetection rate did not improve, thus PPV decreased over
time (from 37.9% (95% C.I.: 36.8; 38.9) in 2004 to 29.4%
(95% C.I.: 27.6; 31.4) in 2009).
3.3. Subgroup analysis by age and by screening round
We stratiﬁed the analysis by age (younger women,
49–54 years, and older women, 55–74 years), and by
screening round (ﬁrst screens in women aged 49–
51 years, and timely subsequent screens in all ages).
3.3.1. Recall rate
In all subgroup analyses recall rate was signiﬁcantly
higher in the DM-group than in the other groups, with
3522 P.A. van Luijt et al. / European Journal of Cancer 49 (2013) 3517–3525the exception of timely subsequent screens (Table 2).
The biggest diﬀerence (p-value < 0.001) was found in
ﬁrst screens with a recall rate for DM-group of 4.6%
compared to 3.3% in SFM-group and 3.2% in SFM
only-group (Table 2).3.3.2. Detection rate
Detection rate was signiﬁcantly higher (p-value
< 0.001) for the DM-group in all subgroup analyses
(Table 2). This was the most pronounced in younger
women (5.1/1000 versus 4.0/1000 in SFM-group and
4.1/1000 in SFM only-group), and in ﬁrst screens (7.0/
1000 in DM-group versus 5.5/1000 in SFM-group and
5.6/1000 in SFM only-group).
3.3.3. PPV
PPV was signiﬁcantly lower in the DM-group than in
the other groups in all subgroup analyses, except in
younger women (Table 2). This diﬀerence (p-value
< 0.001) was largest in older women (35.7% in
DM-group, versus 40.1% in SFM-group and 39.4% in
SFM only-group), and in subsequent screens
(p-value < 0.001) (30.6% in DM-group, versus 33.5%
in SFM-group and 33.4% in SFM only-group).
3.3.4. Stage distribution
In both subgroup analyses signiﬁcantly more DCIS
(p-value < 0.001) were detected in the DM-group
(Fig. 2): in ﬁrst screens 24.5% versus 19.7%
in SFM-group, and 18.2% in SFM only-group;
21.5% in DM-group versus 15.6% in SFM-group and
14.8% in SFM only-group; in younger women 25.9%
in DM-group versus 19.5% in SFM-group, and 19.1%
in SFM only-group; and in older women 19.3% in
DM-group versus 14.5% in SFM-group and 13.2% in
SFM only-group.0%
5%
10%
15%
20%
25%
30%
DM-group SFM-
group
SFMonly-
group
DM-group SFM-
group
SFMonly
group
49-54 55-74
Fig. 2. Proportion of ductal carcinoma in situ (DCIS) (%, with 95% conﬁd
and older women and ﬁrst and timely subsequent screen. DM = digital m
group = DM-screens read by radiologists reading both SFM and DM, SF
DM, SFMonly-group = SFM screens read by radiologists reading only SFThe analysis of the invasive cancers was done sepa-
rately from DCIS, to avoid the large increase in DCIS
to aﬀect the proportions of invasive carcinomas. T1a
was found signiﬁcantly more frequently in the
DM-group in both age-groups (7.2% of invasive
tumours in younger women versus 5.3% in SFM-group
(p-value = 0.02), and 5.6% in SFM only-group
(p-value = 0.04) and 6.9% in older women versus 4.7%
in SFM-group (p-value < 0.001), and 5.0% in SFM
only-group (p-value < 0.001)), as well as in subsequent
screens (4.4% in DM, versus 6.9% in SFM and 5.7%
in SFM only, p-value < 0.001) (Table 3).
In older women, DM detected signiﬁcantly more T1b
tumours (25.0%) than both the SFM-group (22.8%,
p-value < 0.014) and SFM only-group (22.4%
p-value < 0.001).
In younger women, and by stratifying by screening
round, no signiﬁcant diﬀerences in the proportion of
T1b, T1c and T2+ were found.
As a consequence signiﬁcantly less T1c and T2+
tumours were found in the DM-group in older women:
47.8% T1c tumours in DM-group versus in SFM-group
(50.8%, p-value = 0.004), and SFM only-group (52.2%,
p-value < 0.001) and 17.5% T2+ versus 19.0% in SFM-
group (p-value = 0.04). In the timely subsequent screens
the diﬀerence in proportion of T2+ tumours was signif-
icantly lower for DM, 16.8% in DM-group, versus
18.0% in SFM only-group (p-value = 0.04).
The number of screen-detected breast cancers with a
positive node status did not diﬀer signiﬁcantly between
the groups (data not shown).3.4. Variation between regions
We evaluated the results by screening region, the larg-
est spread is found in recall rate, with less variation in- DM-group SFM-
group
SFMonly-
group
DM-group SFM-
group
SFMonly-
group
First Timely subsequent
ence interval) of all screen-detected cancers by a subgroup for younger
ammography screen, SFM = screen-ﬁlm mammography screen, DM-
M-group = SFM-screens read by radiologists reading both SFM and
M.
Table 3
Tumour size distribution of invasive tumours by subgroup, including unclassiﬁed tumours (not shown). p-Values less than 0.05 are considered
signiﬁcant. N = number of cases, % = age adjusted proportion of that size of all detected breast cancers (without the tumours with unknown stage
and size), 95% C.I. = 95% conﬁdence interval, DM = digital mammography, SFM = screen-ﬁlm mammography. DM-group = DM-screens read
by radiologists reading both SFM and DM, SFM-group = SFM-screens read by radiologists reading both SFM and DM, SFM only-group = SFM
screens read by radiologists reading only SFM. T1a = tumour with a diameter up to 0.5 cm, T1b = tumour with a diameter from 0.6 cm up to
1.0 cm, T1c = tumour with a diameter from 1.1 cm up to 2.0 cm, T2+ = any tumour with a diameter larger than 2.0 cm.
Women aged 49–54 Women aged 55–74 First screen Timely subsequent screen
N % p-Value N % p-Value N % p-Value N % p-Value
T1a DM-group 120 7.2 346 6.9 60 7.1 406 4.4
SFM-group 74 5.3 0.02 224 4.7 <0.001 36 4.1 0.0126 262 6.9 <0.001
SFM only-group 174 5.6 0.04 506 5.0 <0.001 81 6.4 0.5184 599 5.7 <0.001
T1b DM-group 302 17.9 1272 25.0 133 16.0 1441 21.9
SFM-group 286 20.2 0.08 1109 22.8 0.014 129 18.4 0.215 1266 22.6 0.38
SFM only-group 582 18.7 0.56 2278 22.4 <0.001 269 17.7 0.3 2591 19.8 <0.001
T1c DM-group 827 50.0 2417 47.8 393 48.0 2851 46.8
SFM-group 708 50.0 0.87 2441 50.8 0.004 342 48.1 0.97 2807 47.1 0.67
SFM only-group 1526 49.4 0.6 5263 52.2 <0.001 727 47.4 0.78 6062 49.6 <0.001
T2+ DM-group 362 21.8 866 17.5 191 25.2 1037 16.8
SFM-group 308 21.3 0.64 916 19.0 0.04 171 23.5 0.44 1053 17.9 0.13
SFM only-group 703 22.6 0.53 1829 18.4 0.23 364 23.8 0.45 2168 18.0 0.04
Table 4
Point estimates and range of variation in regions in recall rate, detection rate and PPV between regions. DM = digital mammography,
SFM = screen-ﬁlm mammography. DM-group = DM-screens read by radiologists reading both SFM and DM, SFM-group = SFM-screens read
by radiologists reading both SFM and DM. PPV = positive predictive value.
Women aged 49–54 Women aged 55–74
DM-group FSM-group DM-group FSM-group
National Range of
variation
National Range of
variation
National Range of
variation
National Range of
variation
Recall rate (per 1000
screens)
2.7 1.7–3.3 2.0 1.3–3.0 1.7 1.2–2.0 1.4 1.1–1.6
Detection rate (per 1000
screens)
5.1 4.4–6.2 4.0 3.4–4.8 6.2 5.5–6.7 5.6 5.0–6.4
PPV (%) 21.4 16.8–29.9 22.1 15.0–30.8 35.7 30.5–47.5 40.1 30.8–54.0
P.A. van Luijt et al. / European Journal of Cancer 49 (2013) 3517–3525 3523detection rate, resulting in varying PPV (Table 4). The
spread is given in overall numbers for the entire study
period. When looking at the range of variation over
the years of the study period we did not ﬁnd evidence
for convergence (data not shown).
4. Discussion
In this study, we were able to conﬁrm the higher
detection rate for DM at the cost of a higher recall rate,
and a slightly lower positive predictive value of recall.
But most importantly we found a signiﬁcant diﬀerence
in the detection of DCIS and T1a tumours.
After an initial increase, the recall rate declined in the
years following ﬁrst introduction of DM. This is in line
with the objective of the Netherlands Expert and Train-
ing Centre for Breast cancer screening (NETCB), advis-
ing to aim for an overall recall rate of approximately 20
per 1000 screens. The NETCB oﬀered one day specialist
training courses for the reading radiologists on reading
DM to obtain this objective.The recall rate in the Dutch programme has stabilised
at 20/1000 screens. In an international perspective, this
is still relatively low.14 Incidence rates of invasive breast
cancer in the Netherlands (both screen-detected and
clinically-detected) remained stable throughout the
study period (270–400/100,000 women, dependent on
age), incidence rates of DCIS increased steadily with
the expansion of DM within the country (from 40–45/
100,000 women to 55–68/100,000 women, dependent
on age).15
When we place the recall rate in the perspective of
long term performance data of the Dutch programme
we see that there has been a pre-existing trend towards
higher recall rates since the second half of the 1990s.
This trend does not appear to be strongly aﬀected by
the introduction of digital screening.13 We conﬁrmed
the results of the earlier studies with regard to recall
rate, detection rate and PPV.2,3,5,7 We did not have the
data to determine the grade of DCIS detected with
DM. However we found a signiﬁcantly higher detection
rate of small invasive tumours.7
Table 5
Summary of some European research on performance of digital mammography, compared to screen-ﬁlm mammography. SFM = the number of
ﬁlm screen examinations analysed, DM = the number of digital screen examinations analysed. RR = recall rate, DR = detection rate,
PPV = positive predictive value, FP = false positive rate.
Author Reference Year Country Study Population RR (%) DR (%) PPV (%) FP (%)
Ongeval 16 2010 Belgium DM 11,355 2.1 0.59 34.9
SFM 23,325 1.58 0.64 30.76
Domingo 12 2011 Spain DM 71,647 6.1 0.43 7.0
SFM 171,191 8.0 0.45 6.0
Sala 17 2009 Spain DM 6074 4.2 0.4 3.8
SFM 12,958 5.5 0.4 5.1
Vinnicombe 10 2009 Great Britain DM 88,478 4.79 0.68 14.3
SFM 31,720 4.43 0.65 14.6
Hambly 9 2009 Republic of Ireland DM 35,204 4.0 6.3 15.7
SFM 153,619 3.1 5.2 16.7
del Turco 11 2007 Italy DM 14,385 4.56 0.72 15.9
SFM 14,385 3.96 0.58 14.7
Skaane 18 2004 Norway DM 6997 3.8 0.59 21.6
SFM 17,911 2.5 0.41 22.1
Vigeland 8 2007 Norway DM 18,239 4.09 0.77 18.5
SFM 324,763 4.16 0.65 15.1
Our results 2013 The Netherlands DM 1,460,344 2.0 0.59 31.2
SFM 1,452,508 1.6 0.51 34.4
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subject, with 152,515 DM being the largest reported
study, we can conﬁrm previous results with regard to
diagnostic precision. We found that PPV is slightly
lower in DM, but steadily increases over time. This must
be due to a learning curve with better understanding of
the ﬁndings on DM. Compared to diﬀerent countries the
recall rate is relatively low in the Netherlands, with a
high PPV (Table 5).6,8–11,16–18
Despite the fact that the radiologists in SFM-group
and SFM only-group did not change the technique,
there is an obviously increasing trend in recall rate and
detection rate. This was in part an intentional policy
communicated during audits and onsite visits by the
NETCB, as a result of the optimisation study carried
out in 2004 and perhaps also inﬂuenced by the recall
rates in DM.2
The sharpest increase was found in the proportion of
DCIS detected. This immediately triggers the concern of
overdiagnosis, as often raised by those opposing screen-
ing. Since this issue can only be elucidated by very long
term evaluations of mortality reduction, at this moment
only modelling studies can be used to predict the impact
of DM on overdiagnosis rate. The clinical consequences
of higher DCIS detection rates have been explored by de
Gelder et al. in 2011.19 She used the data of the feasibil-
ity study from 2004 to 2006 and a statistical model to
predict the mortality reduction and overdiagnosis rate.
The current increase in DCIS is still in line with the data
used in their paper (1.2/1000 screens) and does not alter
their conclusion that increased detection of DCIS by
DM reduces breast cancer mortality by a further 4.4%
at a 21% increased overdiagnosis rate.
The increase in the amount of detected DCIS is stron-
ger in younger women and in ﬁrst screens (aged 50–51).This conﬁrms the previous result of Pisano et al. in the
US that the detection rate is more strongly aﬀected by
DM in younger women.12 In oncology DCIS is still con-
sidered a serious condition and should be treated.20
The increase in the number of DCIS detected is rather
steep. Possibly this is due to a ﬁrst pass eﬀect. This
means that outcomes will be most strongly aﬀected
directly after the introduction of a new technology or
method, comparable to a prevalence screen. The number
of DCIS might stabilise at a lower level in the upcoming
years.
As a result of higher DCIS detection rates, we expect
the detection rates of more advanced tumours to decline
in the upcoming years, although we do expect part of the
DCIS to represent overdiagnosis.19,21 A recent study of
the type of DCIS in the pilot phase showed no shift
towards low grade DCIS, but signiﬁcantly more high
grade DCIS in subsequent screens.7
We also found signiﬁcantly more T1a tumours in the
DM-group. Detection of invasive breast cancer in an
early stage may be beneﬁciary for the results of screen-
ing on mortality reduction, dependent on the grade of
the tumours detected. We have no information on
grade, but Nederend et al. found that DM ﬁnds more
low and intermediate grade tumours.5 The eﬀect of an
increased detection rate on interval cancer rate needs
to be awaited.
A wide range of variance exists when looking at
regions separately. All regions perform within the inter-
nationally set standards. We found no evidence for con-
vergence over time; this is in line with our expectations
as multiple parameters vary (reading radiologists,
changes in equipment etc.).
With the introduction of DM many screening
organisations were stimulated to perform two view
P.A. van Luijt et al. / European Journal of Cancer 49 (2013) 3517–3525 3525examinations, not only at initial screen, but also at reg-
ular follow up screen. In 2010 93% of all participants
were examined using a two view examination. This
change in policy may also have inﬂuenced the perfor-
mance rates of the screening programme.22
In summary, we can conﬁrm earlier results on DM
screening in terms of diagnostic accuracy and can add
that DM detects a signiﬁcantly higher amount of DCIS
and small invasive tumours. The eﬀects of this addi-
tional stage shift on mortality reduction will have to
be awaited. The performance of the Dutch screening
programme in international perspective is good, with a
low recall rate and a high detection rate.
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